JP2020537525A5 - - Google Patents

Download PDF

Info

Publication number
JP2020537525A5
JP2020537525A5 JP2020521290A JP2020521290A JP2020537525A5 JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5 JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020521290 A JP2020521290 A JP 2020521290A JP 2020537525 A5 JP2020537525 A5 JP 2020537525A5
Authority
JP
Japan
Prior art keywords
vector according
monkey
adenovirus vector
replicative
monkey adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020521290A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537525A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/078206 external-priority patent/WO2019076877A1/en
Publication of JP2020537525A publication Critical patent/JP2020537525A/ja
Publication of JP2020537525A5 publication Critical patent/JP2020537525A5/ja
Pending legal-status Critical Current

Links

JP2020521290A 2017-10-16 2018-10-16 複製能力のあるアデノウイルスベクター Pending JP2020537525A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762572927P 2017-10-16 2017-10-16
US62/572,927 2017-10-16
PCT/EP2018/078206 WO2019076877A1 (en) 2017-10-16 2018-10-16 ADENOVIRAL VECTORS FOR REPLICATION

Publications (2)

Publication Number Publication Date
JP2020537525A JP2020537525A (ja) 2020-12-24
JP2020537525A5 true JP2020537525A5 (https=) 2022-06-20

Family

ID=63965644

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521290A Pending JP2020537525A (ja) 2017-10-16 2018-10-16 複製能力のあるアデノウイルスベクター

Country Status (14)

Country Link
US (1) US11268108B2 (https=)
EP (1) EP3697899A1 (https=)
JP (1) JP2020537525A (https=)
KR (1) KR20200066349A (https=)
CN (1) CN111655847A (https=)
AR (1) AR113450A1 (https=)
AU (1) AU2018351308B2 (https=)
BR (1) BR112020007238A2 (https=)
CA (1) CA3079043A1 (https=)
EA (1) EA202090700A1 (https=)
IL (1) IL273753A (https=)
MX (1) MX2020003385A (https=)
SG (1) SG11202003058UA (https=)
WO (1) WO2019076877A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3983012A1 (en) 2019-06-11 2022-04-20 GlaxoSmithKline Biologicals S.A. Mucosal vaccine formulations
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
DK4037708T3 (da) 2019-09-30 2024-09-30 Gilead Sciences Inc HBV-vacciner og fremgangsmåder til at behandle HBV
EP4150344A1 (en) 2020-05-14 2023-03-22 GlaxoSmithKline Biologicals SA Viral biosensors
CN114591922A (zh) * 2022-03-30 2022-06-07 长睿生物技术(成都)有限公司 一种表达狂犬病毒g蛋白的重组黑猩猩源腺病毒及其制备方法
CA3259040A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. HIV Immunogenic Polypeptides and Vaccines and Their Uses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (en) * 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
PL2391638T3 (pl) 2009-02-02 2018-11-30 Glaxosmithkline Biologicals Sa Sekwencje nukleotydowe i aminokwasowe małpiego adenowirusa, zawierające je wektory i ich zastosowania
JP5903045B2 (ja) * 2009-07-31 2016-04-13 パックスバックス, インコーポレイテッド アデノウイルスに基づくベクター
US8865881B2 (en) 2011-02-22 2014-10-21 California Institute Of Technology Delivery of proteins using adeno-associated virus (AAV) vectors
GB201322851D0 (en) * 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
BR112017026523A2 (pt) 2015-06-12 2018-08-14 Glaxosmithkline Biologicals Sa vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado.
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Similar Documents

Publication Publication Date Title
JP2020537525A5 (https=)
Travieso et al. The use of viral vectors in vaccine development
Humphreys et al. Novel viral vectors in infectious diseases
Kosinska et al. Therapeutic vaccination for chronic hepatitis B
JP7326157B2 (ja) Hbvワクチン
Mühlebach Vaccine platform recombinant measles virus
AU2025271193A1 (en) Vaccines against Hepatitis B virus
Bråve et al. Vaccine delivery methods using viral vectors
Clarke et al. Synergistic attenuation of vesicular stomatitis virus by combination of specific G gene truncations and N gene translocations
JP2021182922A5 (https=)
JP2021519791A5 (https=)
Hasanpourghadi et al. COVID-19 vaccines based on adenovirus vectors
JP2020516264A5 (https=)
JP2019526580A5 (https=)
Reynolds et al. Virus-like vesicle-based therapeutic vaccine vectors for chronic hepatitis B virus infection
JP2018536433A5 (https=)
Cobleigh et al. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose
Cobleigh et al. The immune response to a vesicular stomatitis virus vaccine vector is independent of particulate antigen secretion and protein turnover rate
Conforti et al. Are genetic vaccines the right weapon against COVID-19?
JP5675789B2 (ja) 免疫接種のための発現ベクターとしての水疱性口内炎ウイルスの異なる複数の抗原型
JP2021500880A5 (https=)
Hanke New vector and vaccine platforms: mRNA, DNA, viral vectors
Penza et al. The long-lasting enigma of polycytidine (polyC) tract
Flaxman et al. Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse
JP2020537526A5 (https=)